Lumos secures US$5m FebriDx milestone payment as US rollout gains traction

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$5 cardinal milestone pre-payment from its US organisation spouse Phase Scientific, with its FebriDx® point-of-care trial present moving into broader commercialized rollout crossed the United States.

The outgo follows the caller US Food and Drug Administration 510(k) clearance and CLIA waiver for FebriDx®, which satisfies a large milestone nether the companies’ organisation agreement.

Importantly, the funds are a pre-payment for aboriginal merchandise orders alternatively than contiguous revenue, and volition beryllium recognised progressively arsenic acquisition orders are fulfilled and units shipped.

The latest instalment brings full pre-payments received from Phase Scientific to US$7.5 million, gathering connected an earlier US$2.5 cardinal received successful 2025. These earlier funds person already been applied to archetypal orders, including a antecedently announced US$1.3 cardinal acquisition — the largest azygous bid for FebriDx to date.

The CLIA waiver importantly expands the addressable marketplace for FebriDx, allowing it to beryllium utilized successful much than 300,000 healthcare settings crossed the US without the request for analyzable laboratory infrastructure oregon specialised training.

This includes superior attraction clinics, urgent attraction centres, retail wellness clinics and assemblage wellness facilities — a step-change successful accessibility that positions the trial for wide frontline usage successful diagnosing acute respiratory infections.

Lumos noted that FebriDx is already being deployed successful definite urgent attraction networks, including sites operated by WellStreet Urgent Care, wherever it is utilized arsenic an archetypal diagnostic instrumentality for patients presenting with respiratory symptoms.

Chief enforcement serviceman Doug Ward said the milestone shows regulatory advancement is translating into commercialized momentum for Lumos.

“Receipt of the US$5.0 cardinal pre-payment confirms that the 510(k) and associated CLIA waiver person satisfied this captious milestone nether the PHASE Agreement,” helium said. “We look guardant to moving intimately with PHASE and supporting them arsenic we enactment unneurotic to unafraid the wide rollout of FebriDx crossed the US market.”

The update builds connected caller momentum successful Lumos’ US rollout strategy for FebriDx, with increasing request and organisation enactment pursuing the CLIA waiver expansion.

While the FebriDx pre-payment strengthens Lumos’ near-term currency position, the institution emphasised that conversion into gross volition beryllium connected the gait of incoming acquisition orders from Phase Scientific — a cardinal indicator of underlying demand.